The icatibant outcome survey: treatment of laryngeal angioedema attacks

by mm-red | Jul 30, 2020

Objective: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry. Methods: This retrospective analysis was based on...

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey

by mm-red | Jul 30, 2020

Icatibant is used to treat acute hereditary angioedema with C1 inhibitordeficiency types I/II (C1-INH-HAE types I/II) and has shown promise inangioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Datafrom the Icatibant Outcome Survey (IOS) were analysed to...

Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

by mm-red | Jul 30, 2020

The Icatibant Outcome Survey (IOS) is an observational study monitoring safetyand effectiveness of icatibant in the real-world setting. We analyzed safety datafrom 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009and February 2015). Icatibant...

Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey

by mm-red | Jul 29, 2020

Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals

by mm-red | Jul 29, 2020

Background: Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and...